January 31, 2023
RFA-FD-23-027 - Flexible Funding Model-Infrastructure Development and Maintenance for State Manufactured Food Regulatory Programs (U2F) Clinical Trials Not Allowed
FOOD AND DRUG ADMINISTRATION (FDA)
This Notice is to notify applicants that the tables located in Part 2. Full Text of Announcement (Section ! and Section III) are now visible via this Notice for RFA-FD-23-027 "Flexible Funding Model-Infrastructure Development and Maintenance for State Manufactured Food Regulatory Programs (U2F) Clinical Trials Not Allowed)."
Part 2. Full Text of Announcement
Section I. Funding Opportunity Description
A schematic outlining the two funding tracks and the associated funding options available for each track is below:
Base Funding | Optional Add-Ons | Potential Award | ||
MFRPS (Development) | Food Protection Task Force | Dietary Supplements | Special Projects | |
Flat rate: $300,000/year/grantee | Flat rate: $15,000/year/grantee | N/A | N/A | $315,000 |
Base Funding | Optional Add-Ons | Potential Award | ||
MFRPS (Maintenance phase-variable funding) | Food Protection Task Force | Dietary Supplements | Special Projects | |
Level 1: $200,000 | Flat rate: $15,000/year/grantee | Flat rate: $100,000/year/grantee | Flat rate: $100,000/year/grantee | $415,000 |
Level 2: $300,000 | Flat rate: $15,000/year/grantee | Flat rate: $100,000/year/grantee | Flat rate: $100,000/year/grantee | $515,000 |
Level 3: $350,000 | Flat rate: $15,000/year/grantee | Flat rate: $100,000/year/grantee | Flat rate: $100,000/year/grantee | $565,000 |
Section III. Elgibility Information
- Elgible Applicants
Data sources used to determine eligibility:
Manufactured Food Regulatory Program Standards (MFRPS) | FDA for further details):
Criteria | Range | Value |
| Total Non-Contract Inspections (NCI) | <885 firms (<33% percentile) | 1 point |
| >885-1980 firms (>33-66% percentile) | 2 points | |
| >2142 firms (>66% percentile) | 3 points | |
| # of High Risk Inventory | <122 firms (<33% percentile) | 1 point |
| >179-383 firms (>33-66% percentile) | 2 points | |
| >603 firms (>66% percentile) | 3 points | |
| Total FSMA Count by FEI | <704 firms (<33% percentile) | 1 point |
| >1004-1757 firms (>33-66% percentile) | 2 points | |
| >1948 firms (66% percentile) | 3 points | |
| FSMA High Risk Inventory | <190 firms (<33% percentile) | 1 point |
| >212-595 firms (>33-66% percentile) | 2 points | |
| >793 firms (>66% percentile) | 3 points | |
| Total Weighted Contract Inspection Cost | <$1217.4 (<33% percentile) | 1 point |
| >$1253.05-1930.59 (>33-66% percentile) | 2 points | |
| >$1962.41 (>66% percentile) | 3 points | |
| Population based on 2020 Census | >3.011M population (<25% percentile) | 1 point |
| >3.012 - 6.177M population (>25-75% percentile) | 2 points | |
| >6.178M population (>75% percentile) | 3 points |
If you would like to obtain the data set specific to your State program, please email james.betz@fda.hhs.gov .
Janelle Fundersburg
Office of Acquisitions & Grants Services (OAGS)
Food and Drug Administration
Email: Janelle.Fundersburg@fda.hhs.gov
and Human Services (HHS)
